ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicacions en col·laboració amb investigadors/es de Hospital de la Santa Creu i Sant Pau (20)
2023
-
Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 941-958
-
The value of sentinel lymph-node biopsy in women with node-positive breast cancer at diagnosis and node-negative tumour after neoadjuvant therapy: a systematic review
Clinical and Translational Oncology, Vol. 25, Núm. 2, pp. 417-428
2022
-
The value of sentinel lymph-node biopsy after neoadjuvant therapy: an overview
Clinical and Translational Oncology, Vol. 24, Núm. 9, pp. 1744-1754
2019
-
BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study
Journal of Patient-Reported Outcomes, Vol. 3, Núm. 1
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2016
-
High proliferation predicts pathological complete response to neoadjuvant chemotherapy in early breast cancer
Oncologist, Vol. 21, Núm. 2, pp. 150-155
2015
-
Preventive treatments for breast cancer: recent developments
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 257-263
2014
-
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647
2011
-
Hormone-responsive breast cancer
Advances in Therapy, Vol. 28, Núm. 12, pp. 1045-1058
2010
-
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447
-
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
The Lancet, Vol. 375, Núm. 9712, pp. 377-384
2009
-
Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study
Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314
2008
-
Time-to-progression in breast cancer: A stratification model for clinical trials
Breast, Vol. 17, Núm. 3, pp. 239-244
2007
-
Current controversies in the management of early breast cancer
Clinical and Translational Oncology, Vol. 9, Núm. 6, pp. 375-384
2005
-
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy
Clinical Cancer Research, Vol. 11, Núm. 24, pp. 8715-8721
2004
-
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain
Annals of Oncology, Vol. 15, Núm. 2, pp. 201-206
2003
2002
-
Dynamic filters for the spectral analysis of random signals
Measurement Techniques, Vol. 45, Núm. 5, pp. 544-551
-
The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period
Bone Marrow Transplantation, Vol. 29, Núm. 9, pp. 737-743
2000
-
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
Clinical Cancer Research, Vol. 6, Núm. 6, pp. 2356-2362